WealthShield Partners’s Dogwood Therapeutics DWTX Stock Holding History

WealthShield Partners’s Portfolio DWTX Stock Details DWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-1	Closed	–	–	1180
2021 Q1	$0	Buy	+1	New	+$174	﹤0.01%	1199

Other funds holding DWTX

MCM

Masters Capital Management Atlanta, Georgia $3.03B AUM 57.21% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Cetera Advisors Denver, Colorado $12.7B AUM 22.7% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

WealthShield Partners's DWTX Position: Q2 2021 in Review

WealthShield Partners sold out of Dogwood Therapeutics (DWTX) in Q2 2021, closing a stake of 1 share.

WealthShield Partners first reported a position in DWTX in Q1 2021 and held it in 1 quarter. The position peaked at $0 in Q1 2021. 14 funds tracked by Wall St. Rank hold DWTX as of Q2 2021.

WealthShield Partners reported no remaining Dogwood Therapeutics position as of Q2 2021 after selling out during the quarter.
WealthShield Partners sold 1 Dogwood Therapeutics share in Q2 2021.
WealthShield Partners first reported a position in Dogwood Therapeutics in Q1 2021 and held it in 1 quarter.
WealthShield Partners's Dogwood Therapeutics position peaked at $0 in Q1 2021.
14 funds tracked by Wall St. Rank held Dogwood Therapeutics as of Q2 2021.

Based on WealthShield Partners's 13F filing for Q2 2021, filed 6 Aug 2021.